ARIAD to Present at Upcoming Meetings.ARIAD ARIAD Allison Research Index of Art and Design to Present at Leerink Swann Roundtable Conference, "Novel Cancer Therapeutics" & Participate in a Targeted Cancer Therapies Panel at The BIO 2009 International Convention CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ARIA) today announced that it is scheduled to participate in two upcoming meetings on Wednesday, May 20, 2009: the Leerink Swann Roundtable Conference in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. , New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , and the BIO 2009 International Convention in Atlanta, Georgia. Leerink Swann Roundtable Conference ARIAD is scheduled to present at the Leerink Swann Roundtable Conference, "Novel Cancer Therapeutics," at The Roosevelt Hotel in New York City on Wednesday, May 20, 2009. Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD, is scheduled to provide an overview of the Company and its progress in key programs in a corporate presentation at 2:15 p.m. (ET). Dr. Berger will also participate in a panel discussion entitled, "New Developments in Liquid Tumors" at 3:30 p.m. (ET). The ARIAD corporate presentation will be webcast live and can be accessed by visiting the investor relations Investor relations The process by which the corporation communicates with its investors. section of the Company's website at http://www.ariad.com/investor. A replay will be available on the ARIAD website approximately twenty-four hours after the presentation and will be archived for two weeks. 2009 BIO International Convention ARIAD is scheduled to participate in a panel at the 2009 BIO International Convention in Atlanta. Timothy P. Clackson, Ph.D, senior vice president and chief scientific officer at ARIAD, will moderate the panel discussion, "New Developments in Targeted Cancer Therapies," at 10:00 a.m. (ET) on Wednesday, May 20, 2009 in B405, in Building B of the Georgia World Congress Center The Georgia World Congress Center or GWCC is the major convention center in Atlanta. It is the fourth-largest convention center in the United States at 1.4 million ft2 (130,000 m2) and hosts more than a million visitors each year. . About ARIAD ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need - aggressive cancers where current therapies are inadequate. ARIAD's lead product candidate, deforolimus, is an investigational mTOR inhibitor in Phase 3 clinical development in patients with advanced sarcomas Sarcomas Definition A sarcoma is a bone tumor that contains cancer (malignant) cells. A benign bone tumor is an abnormal growth of noncancerous cells. Description A primary bone tumor originates in or near a bone. and is being developed in collaboration with Merck & Co., Inc. ARIAD's second product candidate, AP24534, is an investigational multi-targeted kinase inhibitor in Phase 1 clinical development in patients with hematological hematological, hematologic pertaining to or emanating from blood cells. hematological tests total and differential white cell counts, hematocrit estimation, erythrocyte count. cancers. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-B cell-signaling activity, which may be useful in treating certain diseases. For additional information about the Company, please visit http://www.ariad.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion